None of the participants declared immunodeficiency, immunosuppression treatment, or malignancy
None of the participants declared immunodeficiency, immunosuppression treatment, or malignancy. There were no differences in smoking between both groups. about COVID-19. A random sample, stratified by students, faculty, and administrative staff, was selected. The seroprevalence found was 2.64% (39/1479; 95% CI 1.8C3.4), and the adjusted seroprevalence was 2.89% (95% CI 2.1C3.7). The TAK-285 average age of the students was 23.2 years old, and 47.6 years old for staff. In relation to COVID-19, the following was found: 17.7% pauci-symptomatic, 1.3% symptomatic, 5.5% contact with cases, 4.9% confined, and 0.3% PCR positive. More than 90% complied with preventive measures. The proportion willing to receive the COVID-19 vaccine was 91%. Their sources of information were the Internet (74%) and television (70.1%). They requested that this university offer information (45.1%), training (27%), and provide Personal Protective Gear (PPE) (26.3%). Lastly, 87.9% would repeat the test. A plan was established that included the follow-up of cases and contacts, random sample screening, training courses, bimodal teaching, a specific website, and the distribution of PPE. 0.05. 2.9. Ethical Considerations All the subjects received an informed consent form via email at the time of the invitation to participate in the study, to be read before the test. The study complied with the Ethical Principles for Human Research requirements, and the study protocol (and the rest of the documents) were approved by two Ethics Committees. The study was carried out following the Declaration of Helsinki and the EU Regulation 134 2016/679 on personal data handling. Participation was completely voluntary and all the participants were asked to provide their informed consent in writing and to sign this before the blood sample was taken and before obtaining the barcode. The participants were informed that all the information collected would be anonymous and treated as confidential. The participants could not be identified from your collected material. 3. Results 3.1. Prevalence Study 1479 subjects were studied from your randomized sample. We could not reach out to 21 students from your seroprevalence study, and 7 of them refused to participate, because they lived far from the UA. Therefore, the response ratio was 0.99. Overall, the seroprevalence found for the university or college community of Alicante in the study period from 6 July to 22 July 2020, was 39/1479 (2.64%; 95% CI 1.8C3.4) through the use of the lateral circulation immuno-assay test. The adjusted seroprevalence, according to the data from your Valencian study [38], was 2.89% (95% CI 2.1C3.7) (Table 1). Table 1 Seroprevalence of immunity against SARS-CoV-2 in the University or college community. (%)(%)(%)= 1056) **A390 (48.7)119 (46.7)509 (48.2)Ref AB28 (3.5)10 (3.9)38 (3.6)0.9 (0.7C1.2)0.524B68 (8.5)20 (7.8)88 TAK-285 (8.3)1.1 (0.5C2.3)0.877O315 (39.3)106 (41.6)421 (39.9)0.9 (05C1.5)0.628Smoking *Yes118 (11.6)46 (13.6)164 (12.1)1.2 (0.8C1.7)NSNo903 (88.4)292 (86.4)1195 (87.9) Chronic diseasesYes153 (15.0)107 (31.7)260 (19.1)2.6 (2C3.5) 0.001No868 (85.0)231 (68.3)1099 (80.9) Open in a separate window * Smoking (quantity of cigarettes/day). Age (years). NS (Not Significant). ** Blood group declared by participants. CI = confidence interval. Ref = reference. Blood group A was predominant at 48.2% (509/1056), and 19.1% (260/1359) confirmed suffering from a chronic disease. Globally, the most reported chronic diseases were allergy/asthma (4.8%; 65/1359), cardiovascular (4.1%; 56/1359), and metabolic diseases (3.9%; 53/1359). Allergies were more frequent in the group of students (5%; 51/1021), while in the staff group, cardiovascular diseases were more frequent (10.4%; 35/338). None of the participants declared immunodeficiency, immunosuppression treatment, or Splenopentin Acetate malignancy. There were no differences in smoking between both groups. Still, we found significant differences in the mean quantity of cigarettes/day between the populations: 6 (4.77) in the student group, and 10.2 (7.28) in the staff sample (= 0.001). Table 3 shows the distribution of anti-SARS CoV-2 results in students and faculty and administrative staff. The high prevalence in female students should be noted, as only 16% (4/25) of the positive assessments results were from male students. This could be associated with the male/female ratio of the TAK-285 students. There were four participants who reported a previous positive PCR SARS-CoV-2 test; three of them experienced positive antibody assessments. Only 28% (7/25) of the positive cases reported some prior illness with respiratory symptoms during the 14 days before the study. Table 3 Prevalence of anti-SARS CoV-2 in students and faculty and administrative staff. (%)= 1021) 996 25 1021 Age (years), imply (SD)23.2 (6.4)22.9 (8.3) NSGender, Female712 (71.5)21 (84)733 (71.8)2.1 (0.7C6.2)NSHistory PCR SARS-CoV-2 (+)1 (1.0)2 (8)3 (2.9)0.02 (0.3)0.02Smoking116 (11.6)2 (8)118 (11.6)0.7 (0.2C2.8)NSChronic diseases150 (15.1)3 (12)153 (15)0.8 (0.2C2.6) Self-reported symptoms ?224 (22.5)7 (28.0)219 (21.5)1.3 (0.6C3.2)NSReported contact with 1 TAK-285 confirmed (PCR) COVID-1914 (1.4)3 (12.0)17 (1.7)9.6 (2.6C35.6)0.007Infection disease 12 month previous136 (13.7)5 (20.0)141 (13.8)1.6 (0.5C4.2)NSVaccination 12 months previous158 (15.9)6 (24.0)164 (16.1)1.7 (0.6C4.2)NS Staff (= 338) 324 14 338 Age (years), mean (SD)47.5 (9.4)51.9 (11.8) NSGender, Female180 (55.6)6 (42.7)186 (55.0)0.6 (0.2C1.8)NSHistory PCR SARS-CoV-2 (+)0 (0)1 (7.1)7 (2.0) 0.001Smoking44 (13.6)2 (14.3)46 (13.6)1.1 (0.2C4.9)NSChronic diseases99 (69.2)8 (80.0)107 (69.9)3 (1.02C9)0.036Self-reported symptoms48 (14.8)2 (14.3)39 (11.5)0.9 (0.2C4.5)0.037Reported contact with 1 confirmed (PCR) COVID-192 (0.6)1.